Verdict: Better than nothing, but youre hoping your body does the work
Research Insight: The dual action of GLP-1 receptor agonists on glucose-dependent insulin secretion and glucagon suppression is a cornerstone of their metabolic benefits, as detailed by the American Diabetes Association
[DOI] [PMC free article] [PubMed] [Google Scholar] 16.Meister A, Tate SS
385 doi: (Published 10 April 2024) Cite this as: BMJ 2024;385:e078225 Bjrn Pasternak, principal researcher12, Viktor Wintzell, statistician1, Anders Hviid, professor23, Bjrn Eliasson, associate professor45, Soffia Gudbjrnsdottir, professor56, Christian Jonasson, senior researcher78, Kristian Hveem, professor78, Henrik Svanstrm, senior researcher12, Mads Melbye, professor791011, Peter Ueda, assistant professor1 1 Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden 2 Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark 3 Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark 4 Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden 5 The Swedish National Diabetes Register, Vstra Gtalandsregionen, Gothenburg, Sweden 6 Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden 7 HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Science, NTNUNorwegian University of Science and Technology, Trondheim, Norway 8 HUNT Research Center, Faculty of Medicine, NTNUNorwegian University of Science and Technology, Levanger, Norway 9 Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark 10 Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA 11 Danish Cancer Institute, Copenhagen, Denmark Correspondence to: B Pasternak bjorn ki.se (@Dr_Pasternak on X) Accepted 9 March 2024 Abstract Objective To investigate whether use of glucagon-like peptide 1 (GLP1) receptor agonists is associated with increased risk of thyroid cancer
